Antigen-binding sites of antibody molecules specific for cancer antigens
AssigneeChiron Corporation
InventorDavid B. Ring
Life of this patent
Estimating the term…
Loading patent…
AssigneeChiron Corporation
InventorDavid B. Ring
Estimating the term…
Novel compositions are provided that are derived from antigen-binding sites of immunoglobulins having affinity for cancer antigens. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human tumor cell displaying a MDR phenotype. A number of synthetic molecules are provided that include CDR and FR regions derived from same or different immunoglobulin moieties. Also provided are single chain polypeptides wherein V.sub.H and V.sub.L domains are attached by a single polypeptide linker. The sFv molecules can include ancillary polypeptide moieties which can be bioactive, or which provide a site of attachment for other useful moieties. The compositions are useful in specific binding assays, affinity purification schemes, drug or toxin targeting, imaging, and genetic or immunological therapeutics for various cancers. The invention thus provides novel polypeptides, the DNAs encoding those polypeptides, expression cassettes comprising those DNAs, and methods of inducing the production of the polypeptides.
A monomeric polypeptide that binds to a human tumor cell displaying a multiple-drug resistance, said monomeric polypeptide comprising:
A monomeric polypeptide that binds to a human tumor cell displaying a multiple-drug resistance, said monomeric polypeptide comprising:
A dimeric polypeptide that binds to a human tumor cell displaying a multiple-drug resistance, said dimeric polypeptide comprising:
Dependencies are inferred from the claim text.